|
Post by Clement on Apr 29, 2022 7:44:35 GMT -5
|
|
|
Post by Clement on Apr 29, 2022 7:47:31 GMT -5
Thematic poster session, Monday, May 16, 11:15 AM - 1:15 PM PT: B53/P202 – Comparison of Pharmacokinetics of 3 Doses of Treprostinil Inhalation Powder (Tyvaso DPI) and 3 Doses of Tyvaso in Healthy Normal Volunteers. Presented by Kareem El-Kersh, M.D., University of Nebraska Medical Center.
|
|
|
Post by Clement on Apr 29, 2022 7:48:48 GMT -5
Rapid abstract poster discussion session, Tuesday, May 17, 2:15 PM - 3:45 PM PT: C105/504 – Comparative Effectiveness of Inhaled Treprostinil vs Iloprost in Patients with Pulmonary Arterial Hypertension: An Analysis of U.S. Administrative Claims Data. Presented by Charles D. Burger, M.D., Mayo Clinic Florida.
I'm guessing that there will be at least some mention of Tyvaso DPI here.
|
|
|
Post by Clement on Apr 29, 2022 7:49:41 GMT -5
Sponsored Symposium, Sunday, May 15, 6:30 PM - 9:30 PM PT, A New Frontier in PH-ILD: Screening, Diagnosis, and Treatment Options. Presented by Franck Rahaghi, M.D., MHS, FCCP, Cleveland Clinic Florida; Nicholas Kolaitis, M.D., MAS, University of California, San Francisco; and Steven Nathan, M.D., FCCP, Inova Fairfax Hospital.
Although Tyvaso DPI is not a treatment option today, the topics discussed here will pave the way for rapid uptake of Tyvaso DPI when approved (which might be before this conference starts).
|
|
|
Post by boca1girl on Apr 29, 2022 16:10:12 GMT -5
Sponsored Symposium, Sunday, May 15, 6:30 PM - 9:30 PM PT, A New Frontier in PH-ILD: Screening, Diagnosis, and Treatment Options. Presented by Franck Rahaghi, M.D., MHS, FCCP, Cleveland Clinic Florida; Nicholas Kolaitis, M.D., MAS, University of California, San Francisco; and Steven Nathan, M.D., FCCP, Inova Fairfax Hospital. Although Tyvaso DPI is not a treatment option today, the topics discussed here will pave the way for rapid uptake of Tyvaso DPI when approved (which might be before this conference starts). I think this is a very bullish outlook for T-DPI from UTHR.
|
|